Identification of Surfactant Impact on a Monoclonal Antibody Characterization via HPLC-Separation Based and Biophysical Methods.

analytical characterization methods monoclonal antibody polysorbate 80 surfactant

Journal

Pharmaceutical research
ISSN: 1573-904X
Titre abrégé: Pharm Res
Pays: United States
ID NLM: 8406521

Informations de publication

Date de publication:
22 Mar 2024
Historique:
received: 02 11 2023
accepted: 26 02 2024
medline: 23 3 2024
pubmed: 23 3 2024
entrez: 23 3 2024
Statut: aheadofprint

Résumé

Surfactants, including polysorbates and poloxamers, play a crucial role in the formulation of therapeutic proteins by acting as solubilizing and stabilizing agents. They help prevent protein aggregation and adsorption, thereby enhancing the stability of drug substance and products., However, it is important to note that utilizing high concentrations of surfactants in protein formulations can present significant analytical challenges, which can ultimately affect the product characterization. In our study, we specifically investigated the impact of elevated surfactant concentrations on the characterization of monoclonal antibodies. We employed various analytical techniques including size-exclusion chromatography (SEC), capillary electrophoresis (CE-SDS), a cell based functional assay, and biophysical characterization. The findings of our study indicate that higher levels of Polysorbate 80 (PS-80) have adverse effects on the measured purity, biological activity, and biophysical characterization of biologic samples. Specifically, the elevated levels of PS-80 cause analytical interferences, which can significantly impact the accuracy and reliability of analytical studies. Our study results highlight a significant risk in analytical investigations, especially in studies involving the isolation and characterization of impurities. It is important to be cautious of surfactant concentrations, as they can become more concentrated during common sample manipulations like buffer exchange. Indeed, the research presented in this work emphasizes the necessity to evaluate the impact on analytical assays when there are substantial alternations in the matrix composition. By doing so, valuable insights can be gained regarding potential challenges associated with assay development and characterization of biologics with complex formulations.

Identifiants

pubmed: 38519813
doi: 10.1007/s11095-024-03684-4
pii: 10.1007/s11095-024-03684-4
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. Merck & Co., Inc., Rahway, NJ, USA and its affiliates.

Références

Dimitrov DS. Therapeutic Proteins. In: Voynov V, Caravella JA, editors. Therapeutic Proteins: Methods and Protocols. Totowa, NJ: Humana Press; 2012. p. 1–26.
Mullard A. 2022 FDA approvals. Nat Rev Drug Discov. 2023;22(2):83–8.
doi: 10.1038/d41573-023-00001-3 pubmed: 36596858
Breedveld FC. Therapeutic monoclonal antibodies. The Lancet. 2000;355(9205):735–40.
doi: 10.1016/S0140-6736(00)01034-5
Waldmann TA. Monoclonal Antibodies in Diagnosis and Therapy. Science. 1991;252(5013):1657–62.
doi: 10.1126/science.2047874 pubmed: 2047874
Pinholt C, Hartvig RA, Medlicott NJ, Jorgensen L. The importance of interfaces in protein drug delivery - why is protein adsorption of interest in pharmaceutical formulations? Expert Opin Drug Deliv. 2011;8(7):949–64.
doi: 10.1517/17425247.2011.577062 pubmed: 21557707
Khan TA, Mahler HC, Kishore RS. Key interactions of surfactants in therapeutic protein formulations: A review. Eur J Pharm Biopharm. 2015;97(Pt A):60–7.
doi: 10.1016/j.ejpb.2015.09.016 pubmed: 26435336
Kim HL, McAuley A, McGuire J. Protein effects on surfactant adsorption suggest the dominant mode of surfactant-mediated stabilization of protein. J Pharm Sci. 2014;103(5):1337–45.
doi: 10.1002/jps.23908 pubmed: 24585710
Deechongkit S, Wen J, Narhi LO, Jiang Y, Park SS, Kim J, et al. Physical and biophysical effects of polysorbate 20 and 80 on darbepoetin alfa. J Pharm Sci. 2009;98(9):3200–17.
doi: 10.1002/jps.21740 pubmed: 19388064
Walsh G, Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol. 2006;24(10):1241–52.
doi: 10.1038/nbt1252 pubmed: 17033665
Chung S, Tian J, Tan Z, Chen J, Lee J, Borys M, et al. Industrial bioprocessing perspectives on managing therapeutic protein charge variant profiles. Biotechnol Bioeng. 2018;115(7):1646–65.
doi: 10.1002/bit.26587 pubmed: 29532901
Du Y, Walsh A, Ehrick R, Xu W, May K, Liu H. Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies. MAbs. 2012;4(5):578–85.
doi: 10.4161/mabs.21328 pubmed: 22820257 pmcid: 3499298
Kahle J, Watzig H. Determination of protein charge variants with (imaged) capillary isoelectric focusing and capillary zone electrophoresis. Electrophoresis. 2018;39(20):2492–511.
doi: 10.1002/elps.201800079 pubmed: 29770965
Fekete S, Beck A, Veuthey JL, Guillarme D. Ion-exchange chromatography for the characterization of biopharmaceuticals. J Pharm Biomed Anal. 2015;113:43–55.
doi: 10.1016/j.jpba.2015.02.037 pubmed: 25800161
Neill A, Nowak C, Patel R, Ponniah G, Gonzalez N, Miano D, et al. Characterization of Recombinant Monoclonal Antibody Charge Variants Using OFFGEL Fractionation, Weak Anion Exchange Chromatography, and Mass Spectrometry. Anal Chem. 2015;87(12):6204–11.
doi: 10.1021/acs.analchem.5b01452 pubmed: 25977987
Jaag S, Shirokikh M, Lammerhofer M. Charge variant analysis of protein-based biopharmaceuticals using two-dimensional liquid chromatography hyphenated to mass spectrometry. J Chromatogr A. 2021;1636: 461786.
doi: 10.1016/j.chroma.2020.461786 pubmed: 33326927
Shi RL, Xiao G, Dillon TM, Ricci MS, Bondarenko PV. Characterization of therapeutic proteins by cation exchange chromatography-mass spectrometry and top-down analysis. MAbs. 2020;12(1):1739825.
doi: 10.1080/19420862.2020.1739825 pubmed: 32292112 pmcid: 7188404
Leblanc Y, Ramon C, Bihoreau N, Chevreux G. Charge variants characterization of a monoclonal antibody by ion exchange chromatography coupled on-line to native mass spectrometry: Case study after a long-term storage at +5°C. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1048:130–9.
doi: 10.1016/j.jchromb.2017.02.017 pubmed: 28242492
Zbacnik TJ, Holcomb RE, Katayama DS, Murphy BM, Payne RW, Coccaro RC, et al. Role of Buffers in Protein Formulations. J Pharm Sci. 2017;106(3):713–33.
doi: 10.1016/j.xphs.2016.11.014 pubmed: 27894967
Yang K, Hewarathna A, Geerlof-Vidavsky I, Rao VA, Gryniewicz-Ruzicka C, Keire D. Screening of Polysorbate-80 Composition by High Resolution Mass Spectrometry with Rapid H/D Exchange. Anal Chem. 2019;91(22):14649–56.
doi: 10.1021/acs.analchem.9b03809 pubmed: 31638787
Chou DK, Krishnamurthy R, Randolph TW, Carpenter JF, Manning MC. Effects of Tween 20 and Tween 80 on the stability of Albutropin during agitation. J Pharm Sci. 2005;94(6):1368–81.
doi: 10.1002/jps.20365 pubmed: 15858848
Bartling CM, Andre JC, Howland CA, Hester ME, Cafmeyer JT, Kerr A, et al. Stability Characterization of a Polysorbate 80-Dimethyl Trisulfide Formulation, a Cyanide Antidote Candidate. Drugs R D. 2016;16(1):109–27.
doi: 10.1007/s40268-016-0122-3 pubmed: 26861644 pmcid: 4767715
Toutain-Kidd CM, Kadivar SC, Bramante CT, Bobin SA, Zegans ME. Polysorbate 80 inhibition of Pseudomonas aeruginosa biofilm formation and its cleavage by the secreted lipase LipA. Antimicrob Agents Chemother. 2009;53(1):136–45.
doi: 10.1128/AAC.00500-08 pubmed: 18955535
Singh SM, Bandi S, Jones DNM, Mallela KMG. Effect of Polysorbate 20 and Polysorbate 80 on the Higher-Order Structure of a Monoclonal Antibody and Its Fab and Fc Fragments Probed Using 2D Nuclear Magnetic Resonance Spectroscopy. J Pharm Sci. 2017;106(12):3486–98.
doi: 10.1016/j.xphs.2017.08.011 pubmed: 28843351 pmcid: 6178931
Lakowicz JR. On spectral relaxation in proteins. Photochem Photobiol. 2000;72(4):421–37.
doi: 10.1562/0031-8655(2000)072<0421:OSRIP>2.0.CO;2 pubmed: 11045710 pmcid: 6906610
Randolph TW, Jones LS. Surfactant-protein interactions. Pharm Biotechnol. 2002;13:159–75.
doi: 10.1007/978-1-4615-0557-0_7 pubmed: 11987751
Sinha NJ, Guo R, Misra R, Fagan J, Faraone A, Kloxin CJ, et al. Colloid-like solution behavior of computationally designed coiled coil bundlemers. J Colloid Interface Sci. 2022;606(Pt 2):1974–82.
doi: 10.1016/j.jcis.2021.09.184 pubmed: 34749446
Gill P, Moghadam TT, Ranjbar B. Differential scanning calorimetry techniques: applications in biology and nanoscience. J Biomol Tech. 2010;21(4):167–93.
pubmed: 21119929 pmcid: 2977967
Falke S, Betzel C. Dynamic Light Scattering (DLS): principles, perspectives, applications to biological samples. Radiation in Bioanalysis. 2019;8:173–93.
Otzen D. Protein-surfactant interactions: a tale of many states. Biochim Biophys Acta. 2011;1814(5):562–91.
doi: 10.1016/j.bbapap.2011.03.003 pubmed: 21397738
Parkins DA, Lashmar UT. The formulation of biopharmaceutical products. Pharm Sci Technol Today. 2000;3(4):129–37.
doi: 10.1016/S1461-5347(00)00248-0 pubmed: 10754542
Wang W, Wang YJ, Wang DQ. Dual effects of Tween 80 on protein stability. Int J Pharm. 2008;347(1–2):31–8.
doi: 10.1016/j.ijpharm.2007.06.042 pubmed: 17692480
Zhou X, Fennema Galparsoro D, Østergaard Madsen A, Vetri V, van de Weert M, Mørck Nielsen H, et al. Polysorbate 80 controls Morphology, structure and stability of human insulin Amyloid-Like spherulites. J Colloid Interface Sci. 2022;606:1928–39.
doi: 10.1016/j.jcis.2021.09.132 pubmed: 34695760
Horiuchi S, Winter G. CMC determination of nonionic surfactants in protein formulations using ultrasonic resonance technology. Eur J Pharm Biopharm. 2015;92:8–14.
doi: 10.1016/j.ejpb.2015.02.005 pubmed: 25684280
Lutz H, Wilkins R, Carbrello C. Sterile Filtration: Principles, Best Practices and New Developments. In: Kolhe P, Shah M, Rathore N, editors. Sterile Product Development: Formulation, Process, Quality and Regulatory Considerations. New York, NY: Springer New York. 2013 431–59.
Mahler H-C, Huber F, Kishore RSK, Reindl J, Rückert P, Müller R. Adsorption Behavior of a Surfactant and a Monoclonal Antibody to Sterilizing-Grade Filters. J Pharm Sci. 2010;99(6):2620–7.
doi: 10.1002/jps.22045 pubmed: 20091913

Auteurs

Kaizhu Guo (K)

Biologics Analytical Research and Development, Merck & Co., Inc., Rahway, NJ, 07065, USA. kaizhu.guo@merck.com.

Jing Song (J)

Analytical Enabling Capabilities, Merck & Co., Inc., Rahway, NJ, 07065, USA. jing.song1@merck.com.

Petra Bennington (P)

Cell-Based Sciences, Analytical Research and Development, Merck & Co., Inc., Rahway, NJ, 07065, USA.

Alexander J Pavon (AJ)

Biologics Analytical Research and Development, Merck & Co., Inc., Rahway, NJ, 07065, USA.

Jameson R Bothe (JR)

Biologics Analytical Research and Development, Merck & Co., Inc., Rahway, NJ, 07065, USA.

Hanmi Xi (H)

Analytical Enabling Capabilities, Merck & Co., Inc., Rahway, NJ, 07065, USA.

Rico C Gunawan (RC)

Biologics Analytical Research and Development, Merck & Co., Inc., Rahway, NJ, 07065, USA.

Classifications MeSH